|Day Low/High||6.41 / 6.95|
|52 Wk Low/High||3.96 / 19.00|
Company outlines new strategic imperatives and value drivers
Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom; Company initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients
In recent trading, shares of XOMA Corp have crossed above the average analyst 12-month target price of $1.09, changing hands for $6.24/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Company Reached Agreement with MHRA on General Trial Design for Multi-dose Testing in Children 2 Years and Older in the United Kingdom
Novel first-in-class antibody enters clinic for second rare hypoglycemic indication
Data supports continued development of XOMA 129 as a novel targeted therapy for the treatment of hypoglycemic conditions
Trade-Ideas LLC identified XOMA (XOMA) as a weak on high relative volume candidate
Xoma stock is gaining on heavy trading volume early Thursday afternoon after the company reported its 2015 fourth quarter results after yesterday’s closing bell.
Xoma stock is jumping in after-hours trading on Wednesday after the company reported its 2015 fourth quarter results.
Company Advancing Its Endocrine Portfolio After Completing Divestiture of Non-Core Assets